Minerva (Cyproterone Acetate, Ethinylestradiol)

Minerva, a combined oral contraceptive, is indicated for conditions that involve hormonal regulation and androgen‑dependent skin disorders.

• Contraception: Prevents pregnancy by suppressing ovulation in women of reproductive age.
• Acne vulgaris: Reduces inflammatory acne lesions by decreasing androgen activity in the skin.
• Hirsutism: Decreases excess facial and body hair growth through anti‑androgen effects.
• Androgen‑dependent skin disorders: Improves symptoms such as seborrhoea by lowering androgen stimulation.

• Minerva combines cyproterone acetate, a progestogen with anti‑androgen activity, and ethinylestradiol, a synthetic estrogen. Ethinylestradiol provides negative feedback to the hypothalamic‑pituitary‑ovarian axis, suppressing follicle‑stimulating hormone and luteinizing hormone release, thereby preventing ovulation. Cyproterone acetate binds to androgen receptors, blocking androgen binding, and also reduces gonadotropin secretion, leading to decreased ovarian androgen production.

Minerva may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Nausea: Mild to moderate stomach upset, especially during the first cycles.
• Headache: Transient tension‑type headaches reported by many users.
• Breast tenderness: Sensitivity or swelling of breast tissue.
• Spotting or irregular bleeding: Breakthrough bleeding, particularly in the initial months.

Serious or Rare Side Effects

• Venous thromboembolism: Deep vein thrombosis or pulmonary embolism, requiring immediate medical attention.
• Severe allergic reaction: Anaphylaxis or angioedema, presenting with rash, swelling, and breathing difficulty.

Before prescribing Minerva, clinicians should consider several safety precautions to minimize risk.

• Pregnancy contraindication: Product is classified as pregnancy category X and must not be used during pregnancy.
• Smoking and cardiovascular risk: Avoid in women over 35 who smoke due to increased thrombotic risk.
• Liver disease: Use with caution in patients with hepatic impairment.
• Migraine with aura: Contraindicated because of heightened stroke risk.
• Drug interactions: Review concomitant medications for CYP3A4 inducers or anticoagulants.
• Store at ambient temperature: Keep tablets below 25 °C in the original pack, protected from moisture.

Minerva can interact with several medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): May reduce contraceptive efficacy.
• Anticoagulants (e.g., warfarin): Combined use can increase bleeding risk.
• Additional estrogen‑containing products: May amplify estrogen‑related adverse events.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors: May increase risk of mood changes.
• Antihypertensives: Hormonal effects can alter blood pressure control.
• Certain antiretrovirals (e.g., protease inhibitors): May affect hormone levels and efficacy.